Apex Labs Files for US Patent Protecting Psychedelic Drug Delivery System
Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with psilocybin is pleased to announce the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO). The patent application applies to APEX’s uniquely formulated capsule which will be used for PATHFINDER-52 and SUMMIT-90 phase 2b clinical trials and in APEX’s Early Access Program (EAP). The data shows that APEX’s innovative approach improves bioavailability, oxidative stability and thermal stability for psilocybin and other psychedelics at both low and high doses.
“I am incredibly proud of the APEX research and development team for their years of hard work to develop our innovative drug delivery system,” says Tyler Powell, CEO and co-Founder. “This patent application is a core pillar of our intellectual property strategy, paving the way for strong and sustainable commercial sales.”
In Q1 2024 APEX received its Controlled Drugs and Substances Dealer’s Licence (DL) which authorizes the organization to sell APEX drug through Health Canada’s Special Access Program (SAP) providing access to treatment for Canadians outside of clinical trials.
“The team has worked diligently to hit this milestone in our drug development program with the unique capsule empowering dosing of APEX drugs in-clinic and at home,” says Dr. Orion Lekos, Chief Science Officer and co-Founder. “We are confident the increased bioavailability and effectiveness of our drug assets will position APEX as a leader in the sector.”
Author
